Skip to main content
. 2013 Aug 26;98(11):E1852–E1860. doi: 10.1210/jc.2013-2292

Table 2.

Allelic Frequency of BRAF Mutations in Thyroid Cancers

Tumor Type Specimen Type Mutation Type BRAF Mutant Allele Frequency BRAF Mutation Frequencya Concurrent Mutations (Allele Frequency)
PTC FFPE BRAF V600E 36% 72%
PTC FRZ BRAF V600E 44% 88%
PTC FRZ BRAF V600E 43% 86%
PTC FRZ BRAF V600E 39% 78%
PTC FFPE BRAF V600E 37% 74% TP53 (40%)
PTC FRZ BRAF V600E 36% 72%
PTC FRZ BRAF V600E 34% 68%
PTC FRZ BRAF V600E 31% 62%
PTC FFPE BRAF V600E 29% 58%
PTC FFPE BRAF V600E 22% 44%
PTC FFPE BRAF V600E 18% 36%
PTC FFPE BRAF V600E 35% 70%
PTC FRZ BRAF V600_R603 delVKSR, T599I 42% 84%
PTC FFPE BRAF V600E 39% 78% PIK3CA (38%), TP53 (31%)
PMC (PTC) FNA BRAF V600E 18% 36%
FLUS (PTC) FNA BRAF V600E 17% 34%
PTC, FV FFPE BRAF K601E 30% 60%
PTC, FV FFPE BRAF V600E 29% 58%
PDC FRZ BRAF V600E 48% 96%
ATC FRZ BRAF V600E 20% 40%
ATC FFPE BRAF V600E 23% 46% TP53 (60%)
ATC FFPE BRAF V600E 34% 68% PIK3CA (16%)
ATC FFPE BRAF K601E 38% 76%
ATC FFPE BRAF V600E 5.2% 10.4% TP53 (4.9%)
ATC FRZ BRAF V600E 5.9% 11.8% TP53 (8.8%); PIK3CA (11%)
ATC FRZ BRAF V600E 8.0% 16.0%

Abbreviations: FLUS, follicular lesion of undetermined significance on FNA; FRZ, frozen tissue; PMC, positive for malignant cells on FNA; FV, follicular variant.

a

Based on the assumption that the mutation is heterozygous.

HHS Vulnerability Disclosure